Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]

Philip A. Thompson, MBBS, Michael J Keating, MBBS, Nitin Jain, MD, Alessandra Ferrajoli, MD, Tapan M. Kadia, MD, Prithviraj Bose, MD, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 358.

https://doi.org/10.1182/blood-2019-129230

Published: 2019

Journal Articles

Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Blood (2019) 134 (Supplement_1): 4161.

https://doi.org/10.1182/blood-2019-127923

Published: 2019

Journal Articles

Economic Burden of End Organ Damage Among Patients with Sickle Cell Disease in the US

Xue Song, Andrew D. Campbell, MD, Ze Cong, PhD, Irene Agodoa, MD, Diane Martinez, DrPH, MPH, Carolyn R. Lew, PhD, Danae Black, Helen Varker, Chris Chan, Sophie M. Lanzkron, MD

Blood (2019) 134 (Supplement_1): 3388.

https://doi.org/10.1182/blood-2019-127173

Published: 2019

Journal Articles

Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study

Paolo Caimi, MD, Deepa Jagadeesh, MDMPH, Kirsten Marie Boughan, DO, Robert M. Dean, MD, Brenda Cooper, MD, Brad Pohlman, MD, Molly M Gallogly, MDPhD, Sarah L. Ondrejka, DO, Erika Moore, MD, Kwadwo Asare Oduro, MDPhD, Eric D. Hsi, MD, Marcos de Lima, MD, Brian T. Hill, MD PhD

Blood (2018) 132 (Supplement 1): 397.

https://doi.org/10.1182/blood-2018-99-115587

Published: 2018

Journal Articles

Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Blood (2018) 132 (Supplement 1): 905.

https://doi.org/10.1182/blood-2018-99-116078

Published: 2018

Journal Articles

The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials

M. Judith Peterschmitt, MD, Selena Freisens, MD, Audrey W Hou, PharmD, Lisa Underhill, MS, Meredith C. Foster, ScD, Sebastiaan J.M. Gaemers, MD

Blood (2018) 132 (Supplement 1): 3692.

https://doi.org/10.1182/blood-2018-99-118319

Published: 2018

Journal Articles

Infectious Complications after High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Hematologic Malignancies in a 12-Year Period in Hospital Britanico, Uruguay

Ana Carolina Oliver, MD, Eloisa Riva, MD, Ricardo Fabian Mosquera, MD, Silvia Pierri, MD, Sebastian Galeano, MD, Ada Caneiro, MD, Laura Bello, Dra, Carolina Errecarte, MD, Regis Gai, MD, Andrew Miller, Pablo J. Muxi, MD

Blood (2018) 132 (Supplement 1): 5836.

https://doi.org/10.1182/blood-2018-99-112220

Published: 2018

Journal Articles

Determination of Phase 3 Dose for X4P-001 in Patients with WHIM Syndrome

David C Dale, MD, Frank Caleb Firkin, MD, Audrey Anna Bolyard, RN, BS, Merideth L. Kelley, MSc, Emily Dick, BA, Sonja Hartmann, PhD, Karen Brown, PhD, Tarek M Ebrahim, MD, Kenneth J Gorelick, MD, Sudha Parasuraman, MD

Blood (2018) 132 (Supplement 1): 1102.

https://doi.org/10.1182/blood-2018-99-119840

Published: 2018

Journal Articles

Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 815.

https://doi.org/10.1182/blood.V130.Suppl_1.815.815

Published: 2017

Journal Articles

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Jia Ruan, MD PhD, Peter Martin, FRCPC, MD MS, Paul J Christos, Dr.P.H., M.S., Leandro Cerchietti, MD, Bijal D. Shah, MD, Stephen J. Schuster, MD, Wayne Tam, MD PhD, Amelyn Rodriguez, BSN, RN, OCN, David Hyman, Maria Nieves Calvo Vidal, PhD, Lidia Roman Gonzalez, Sonali M. Smith, MD, Jakub Svoboda, MD, Richard R. Furman, MD, Morton Coleman, MD, John P. Leonard, MD

Blood (2017) 130 (Supplement 1): 154.

https://doi.org/10.1182/blood.V130.Suppl_1.154.154

Published: 2017

Journal Articles

Portal Vein Thrombosis in Adult Omani Patients-a Retrospective Study

Khalid Al Hashmi, MD, Lamia Al Aamri, Anil Pathare, MD PhD FCPS, MBBS, Al Lamki Sulayma, Murtadha K. Al-Khabori, BSc,MDFRCPC,MSc

Blood (2017) 130 (Supplement 1): 4909.

https://doi.org/10.1182/blood.V130.Suppl_1.4909.4909

Published: 2017

Journal Articles

Relapsing Thrombotic Thrombocytopenic Purpura: A Single Center Experience

Arielle L Heeke, MD, Craig M. Kessler, MD, Catherine Broome, MD

Blood (2016) 128 (22): 3732.

https://doi.org/10.1182/blood.V128.22.3732.3732

Published: 2016

Journal Articles

Multicenter, Open-Label Phase I Clinical Study of Oral Rigosertib in Japanese Patients with Recurrent/Relapsed or Refractory Myelodysplastic Syndromes: Tolerability, Efficacy, and Pharmacokinetic Profiles

Kenichi Ishizawa, MD PhD, Kensuke Usuki, MD PhD, Kiyoshi Ando, MD PhD, Yasunori Ueda, MD PhD, Toru Kiguchi, MD PhD, Naokuni Uike, MD PhD, Yasushi Onishi, MD PhD, Hiroatsu Iida, MD PhD

Blood (2016) 128 (22): 5538.

https://doi.org/10.1182/blood.V128.22.5538.5538

Published: 2016

Journal Articles

Diagnosis of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease of the Liver: Problems of Interpretation

Liisa Volin, MD PhD, Riitta Niittyvuopio, MD PhD, Jouni Heiskanen, MD, Vesa Lindstrom, MD, Leila Sahlstedt, MD PhD, Tapani Ruutu, MD PhD

Blood (2015) 126 (23): 1918.

https://doi.org/10.1182/blood.V126.23.1918.1918

Published: 2015

Journal Articles

Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG)

Blood (2014) 124 (21): 4699.

https://doi.org/10.1182/blood.V124.21.4699.4699

Published: 2014

Journal Articles

Gallstones in Sickle Cell Disease: A Single Institution Experience

Thomas Coats, Kate Gardner, Swee Lay Thein, MBBS, DSc

Blood (2014) 124 (21): 4939.

https://doi.org/10.1182/blood.V124.21.4939.4939

Published: 2014

Journal Articles

A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory (IMiD) Drug Lenalidomide Produces Durable Responses in Patients with Heavily Pretreated Relapsed Lymphoma

Brenda Ernst, MD, Amylou Constance Dueck, PhD, Angela Toro, NP, Patrick B. Johnston, MD PhD, Thomas Haberman, MD, Jose F. Leis, MD PhD, Joseph R. Mikhael, MD, Grzegorz S. Nowakowski, MD, Joseph P. Colgan, MD, Luis F. Porrata, MD, James L Slack, MD, Stephen M. Ansell, MD PhD, Thomas E. Witzig, MD, Craig B. Reeder, MD

Blood (2014) 124 (21): 3100.

https://doi.org/10.1182/blood.V124.21.3100.3100

Published: 2014

Journal Articles

Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report

Jia Ruan, MD PhD, Peter Martin, MD, Bijal D. Shah, MD, Stephen J. Schuster, MD, Sonali M. Smith, MD, Richard R Furman, MD, Paul Christos, DrPH, Amelyn Rodriguez, RN, Louisa Drake, Jakub Svoboda, MD, Jessica Lewis, PA-C, Orel Katz, PA-C, Morton Coleman, MD, John P. Leonard, MD

Blood (2014) 124 (21): 625.

https://doi.org/10.1182/blood.V124.21.625.625

Published: 2014

Journal Articles

Acute Cholecystitis Occurs More Commonly Than Expected Following Allogeneic Hematopoietic Stem Cell Transplantation and Is Ineffectively Diagnosed Using Abdominal Ultrasound

Stephen J. Bagley, MD, Alison R. Sehgal, MD, Noelle V. Frey, MD, Saar Gill, MD, PhD, Elizabeth Hexner, MD, Alison W. Loren, MD, James K. Mangan, MD, PhD, David L. Porter, MD, Ran Reshef, MD, Edward A. Stadtmauer, MD, Selina Luger, MD

Blood (2013) 122 (21): 2046.

https://doi.org/10.1182/blood.V122.21.2046.2046

Published: 2013

Journal Articles

Cyclophosphamide Maintenance Therapy Is a Safe and Effective Alternative In Multiple Myeloma Patients Who Undergo Autologous Stem Cell Transplantation

Michael T. Byrne, DO, Jan S Moreb, MD

Blood (2013) 122 (21): 5373.

https://doi.org/10.1182/blood.V122.21.5373.5373

Published: 2013

NARROW

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]

Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Economic Burden of End Organ Damage Among Patients with Sickle Cell Disease in the US

Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study

Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials

Infectious Complications after High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Hematologic Malignancies in a 12-Year Period in Hospital Britanico, Uruguay

Determination of Phase 3 Dose for X4P-001 in Patients with WHIM Syndrome

Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Portal Vein Thrombosis in Adult Omani Patients-a Retrospective Study

Relapsing Thrombotic Thrombocytopenic Purpura: A Single Center Experience

Multicenter, Open-Label Phase I Clinical Study of Oral Rigosertib in Japanese Patients with Recurrent/Relapsed or Refractory Myelodysplastic Syndromes: Tolerability, Efficacy, and Pharmacokinetic Profiles

Diagnosis of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease of the Liver: Problems of Interpretation

Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG)

Gallstones in Sickle Cell Disease: A Single Institution Experience

A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory (IMiD) Drug Lenalidomide Produces Durable Responses in Patients with Heavily Pretreated Relapsed Lymphoma

Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report

Acute Cholecystitis Occurs More Commonly Than Expected Following Allogeneic Hematopoietic Stem Cell Transplantation and Is Ineffectively Diagnosed Using Abdominal Ultrasound

Cyclophosphamide Maintenance Therapy Is a Safe and Effective Alternative In Multiple Myeloma Patients Who Undergo Autologous Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only